Aura Biosciences Q1 net loss widens on higher R&D costs

Aura Biosciences

11/05/2026 21:08

Overview

U.S. biotech firm's Q1 net loss widened yr/yr due to higher R&D expenses

Company completed $299 mln equity financing, cash expected to fund operations into 2H 2028

Natalie Holles appointed CEO and President, succeeding founder in previously announced change

Outlook

Company expects to complete Phase 3 CoMpass trial enrollment by mid-2026

Aura anticipates topline data from CoMpass trial in 2H 2027

Company expects current cash position to fund operations into 2H 2028

Result Drivers

R&D COSTS - Higher research and development expenses driven by ongoing Phase 3 trial of bel-sar in early choroidal melanoma and related manufacturing and development costs

G&A EXPENSES - General and administrative expenses rose due to higher personnel costs and increased professional fees

Company press release: ID:nGNXbhh5bS

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$33.69 mln
Q1 Operating Expenses
$34.87 mln
Q1 Operating Income
-$34.87 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Aura Biosciences Inc is $22.00, about 161.9% above its May 8 closing price of $8.40

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)